首页 › 基金 › Cormorant Asset Management, LP › CRBP
Cormorant Asset Management, LP 对 CRBP 的持仓历史
CORBUS PHARMACEUTICALS HLDGS · 医疗保健
Cormorant Asset Management, LP 在 Q3 2026 的 13F 申报中披露持有 CRBP(CORBUS PHARMACEUTICALS HLDGS)2,344,971 股,市值约 US$16.0M,约占其申报组合的 1.14%,在其申报持仓中市值排名第 28 位。 Cormorant Asset Management, LP 最近 11 个申报季度中有 11 个季度披露了 CRBP 持仓,最早可追溯至 Q1 2024。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
Cormorant Asset Management, LP 对 CRBP 的持仓演变
Cormorant Asset Management, LP 于 Q1 2024 首次披露 CRBP 持仓:2,025,000 股(约 US$79.5M)。 该持仓在 Q2 2024 达到峰值 2,025,000 股,市值约 US$91.6M。 在 11 次申报中,Cormorant Asset Management, LP 1 次增持、1 次减持、8 次保持不变。 最近一期申报(Q3 2026)显示持股 2,344,971 股、市值约 US$16.0M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q1 2024 | 2.02M | $79.46M | 新进 |
| Q2 2024 | 2.02M | $91.63M | 持有 |
| Q3 2024 | 2.38M | $49.00M | 增持 |
| Q4 2024 | 2.38M | $28.02M | 持有 |
| Q1 2025 | 2.38M | $12.61M | 持有 |
| Q2 2025 | 2.38M | $16.39M | 持有 |
| Q3 2025 | 2.38M | $30.04M | 持有 |
| Q4 2025 | 2.34M | $19.09M | 减持 |
| Q1 2026 | 2.34M | $22.02M | 持有 |
| Q2 2026 | 2.34M | $22.00M | 持有 |
| Q3 2026 | 2.34M | $15.99M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 CRBP 与 13F 数据
CRBP(CORBUS PHARMACEUTICALS HLDGS)属于医疗保健行业。我们追踪的基金中还有 25 只申报持有 CRBP,申报仓位最大的包括:MPM BioImpact LLC (US$11.4M), Jones Hill Capital LP (US$6.0M), DIADEMA PARTNERS LP (US$5.5M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 CRBP 的基金
- MPM BioImpact LLC 1.67M 股 · $11.37M · Q3 2026
- Jones Hill Capital LP 886.43K 股 · $6.05M · Q3 2026
- DIADEMA PARTNERS LP 800.00K 股 · $5.46M · Q3 2026
- Sio Capital Management, LLC 766.36K 股 · $5.23M · Q3 2026
- Exome Asset Management LLC 190.71K 股 · $1.30M · Q3 2026
- Prosight Management, LP 168.38K 股 · $1.15M · Q3 2026
更多关于 Cormorant Asset Management, LP
常见问题
How long has Cormorant Asset Management, LP held CRBP?
Cormorant Asset Management, LP has disclosed CRBP holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
What is Cormorant Asset Management, LP's current position in CRBP?
As of Q3 2026, Cormorant Asset Management, LP holds 2.34M shares of CRBP (CORBUS PHARMACEUTICALS HLDGS), valued at $15.99M, representing 1.14% of its reported portfolio and ranking #28.
Has Cormorant Asset Management, LP been buying or selling CRBP?
In the latest 13F filing (Q3 2026), Cormorant Asset Management, LP held unchanged its position in CRBP. The position peaked in Q2 2024 at 2.02M shares.
Which other funds hold CRBP?
Other major institutional holders of CRBP include MPM BioImpact LLC, Jones Hill Capital LP, DIADEMA PARTNERS LP, among 25 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.